NLX-101
Rett Syndrome & Fragile X Syndrome
Phase 1Active
Key Facts
About Neurolixis
Neurolixis is a privately held, Paris-based biotech advancing a focused pipeline of first-in-class, highly selective serotonin 5-HT1A receptor agonists for CNS disorders. Its lead assets include NLX-112 (Phase 2 for Parkinson's disease dyskinesia), NLX-101 (Phase 1 for Rett and Fragile X syndromes), and NLX-204 (preclinical for depression/pain). The company is funded primarily through non-dilutive grants from prestigious foundations like The Michael J. Fox Foundation and the Rett Syndrome Research Trust, demonstrating strong validation of its scientific approach.
View full company profile